The Corning Scientific Seminar Series is a series of free, online technical presentations that provide novel tips, best practices and proven techniques to help advance your research. Delivered by scientists to scientists, these one-hour broadcasts offer useful information and tips for lab technicians and researchers.
3D culture is gaining pivotal importance for attaining in vivo-like conditions in a dish to study developmental cues as well as therapeutic possibilities. Organoid development promises to be one of the most important research tools in the near future. This presentation will cover:
• Methodologies used in organoid culture
• Matrices for growing organoids
• Recovery of organoids for downstream applications
Dr. Nitin Kulkarni is a member of the Scientific Support team at Corning Life Sciences. He has a Ph.D. in Biology and has worked on engineering transgenic mouse models for autoimmune diseases during his post-doctoral research at the Beth Israel Deaconess Medical Center in Boston, MA.
In his current role, he supports researchers with applications related to cell culture including advanced surfaces and extracellular matrices, genomics, drug discovery and bioprocesses.
Three-dimensional cell cultures, and multicellular tumor spheroids in (MCTS) in particular, have recently become a widely used tool for preclinical anticancer drug testing in high-throughput screening (HTS) setup. However, even though MCTS have been applied for HTS, their use has been limited to simple assays, such as assessing cell viability or inhibition of growth.
This webinar will cover new approaches to MCTS-based HTS. It will present a new, robust viability assay, well-suited for HTS and based on green fluorescent protein (GFP) used as a surrogate marker of spheroid viability. It will also review a first-ever approach to obtain information-rich transcriptomic data from drug-treated MCTS on a large scale. In addition, the presenter will demonstrate how this novel platform resulted in the identification of previously unrecognized, context-dependent drug responses of cancer cells and in findings with potential clinical relevance.
In summary, this webinar will demonstrate new ways of how MCTS-based HTS can be used to provide unique insights into context-dependent biology and cellular drug responses.
About the Presenter:
Wojciech Senkowski will soon complete his Ph.D. in Medical Sciences at Uppsala University, Sweden. In his work, he looks for applications of various tumor spheroid models in high throughput drug screening. For his work, Wojciech has received the AACR Scholar-in-Training Award. He was also a presenter and expert panelist at the Genetic Engineering & Biotechnology News webinar on 3D cell cultures, sponsored by Corning in February of 2016.
Webinar: The Impact of Soluble Factors and Substrate on Cell Culture: Media Additives, Growth Factors, and Surface
From basal media with feeder layers or serum to highly defined recombinant growth factors, cytokine, and extracellular matrix, there are many ways to grow the same cell type. The choice is dependent on scale, cost, control, skill, and regulatory factors.
This webinar will cover:
- Different ways to grow the same cell type
- The actual material costs of various methods
- Methods used to optimize formulations
Kevin Kelly graduated from Hawaii Pacific University and for 15 years worked on process scale-up and optimization for extracellular matrix proteins, growth factors, cytokines, antibodies, ELISA kits, and Corning® BioCoat™ products.
Currently he provides applications support for invasion, migration, permeability, transport, differentiation, and metabolism assays.
Corning was pleased to have recently sponsored a GEN webinar highlighting the latest techniques for 3D cell culture in cancer research.
The use of 3D cell cultures has been rising sharply in recent years from its initial introduction, over two decades ago. Because 3D cultures more accurately mimic the cellular environment, they can be used to study various forms of cancer by fostering the growth of organoids that replicate key properties of in vivo organ systems or the original tumors from which they were derived.
In addition, many 3D cultures are amenable to large-scale drug screens for rapid detection of phenotypic or genetic changes associated with therapeutic compounds—an approach that opens the door for the use of 3D culture as an integral part of personalized medicine.
In this GEN webinar, panelists discussed how the latest 3D cell culture methods have facilitated breakthroughs in their research projects.
Marshall Kosovsky, Ph.D., Global Scientific Support Manager for Corning Life Sciences, will give a brief introduction into advances in Corning’s 3D culturing solutions.
Ömer H. Yilmaz, M.D., Ph.D., Assistant Professor of Biology at the Massachusetts Institute of Technology, will describe his work on how adult stem cells and their microenvironment adapt to diverse conditions within the context of tissue regeneration and cancer initiation through the use of ex vivo intestinal organoid assays.
Wojciech Senkowski, Doctoral candidate in the Department of Medical Sciences at Uppsala University in Sweden, will discuss his current work, which looks for applications of various tumor spheroid models in high-throughput drug screening for ways to identify novel compounds that target these cell populations
This presentation describes critical factors for selecting microcarriers, as well as starting protocols to help you optimize the attachment and expansion of cells in spinner flask and bioreactor environments.
In addition, you’ll learn about new dissolvable microcarrier technology, which provides unique advantages for cells that cannot be easily separated from standard microcarriers.
Jennifer Weber is a senior development scientist with Corning Life Sciences. She has helped develop a variety of products for culturing advanced cell types including Corning® Synthemax™, a synthetic, xeno-free surface, and Corning stemgro ® hMSC, a serum-free, chemically defined medium for hMSC culture.
She recently transitioned to microcarrier product development and customer support for bioprocess applications. As part of this role, she facilitates customer adoption of Corning products for specific applications through protocol development, on-site technical support, and in-house customer-driven projects.
Cell culture media is required for successful and reproducible research but the catalog is full of acronyms and various formulation tables. Classical mammalian cell culture media formulations are very diverse both in terms of the number available and the concentration of constituents. Additionally, each medium was designed for specific cell types and culturing conditions.
This webinar will cover:
•The composition, characteristics, environmental factors, and additional supplements required to create optimal conditions for growth and productivity.
•Determining the right formulation for your application.
•Serum usage and helpful tips for optimizing your culture conditions.
Brian Posey is a Product Development Manager for cell culture media at Corning Life Sciences. Brian has over 10 years experience in cell biology and industrial scale cGMP manufacturing of both liquid and powder cell culture media. Since joining Corning in 2012, Brian has led numerous innovative technology projects for the media business ranging from customer technology transfer for production scale-up to developing new serum-free media for industrial and stem cell lines.
Organic anion-transporting polypeptides (OATPs) play an important role in hepatic uptake of a variety of clinically important drugs. The significant differences in OATP/Oatp-dependent drug transport between human and preclinical species presents a challenge for interspecies extrapolation of drug pharmacodynamics and pharmacokinetics. The assessment of the difference in hepatic uptake between species using an in vitro model is highly desired to support mechanistic studies and to understand the differences observed between species in vivo.
The Corning® TransportoCells™ model has demonstrated significant value in terms of supporting in vitro assessment of drug interaction with SLC transporters in drug discovery and development. Recently, several animal species of Oatps were introduced into the Corning TransportoCells portfolio. This webinar will focus on the development of the newly available animal species and characterization of the differences in OATP/Oatp in substrate specificity and kinetics using this "thaw and go" model.
Three-dimensional (3D) cell culture models, which offer significant improvements over traditional two dimensional monolayer cell culture in terms of maintaining morphological and functional characteristics of tissue, are increasingly being incorporated in drug discovery as model systems to study disease or for screening for chemotherapeutic efficacy or drug toxicity. This presentation will demonstrate the use of Corning® spheroid microplates to culture and assay spheroids in a rapid and highly reproducible format that enables the formation of a single multi-cellular spheroid, centered in each well.
Corning spheroid microplates are multiple well, cell culture plates with opaque walls and unique clear, round well-bottom geometry that utilize the Corning Ultra-Low Attachment surface coating. The coating is hydrophilic, biologically inert and non-degradable. Representative data will be shown exhibiting the use of the spheroid microplate in more specialized assays including the formation of neurospheres from neural stem cells (NSCs), a valuable model to study neurogenesis and neural development, as well as analysis of NSC proliferation and migration. We will also demonstrate the formation of hepatospheres using Corning HepatoCells, an immortalized alternative to primary human hepatocytes, in combination with the SCREEN-WELL Hepatotoxicity library from Enzo Life Sciences for 3D hepatotoxicity screening. Finally, we will show the use of the Corning spheroid microplate to generate spheroids comprised of multiple cell types, demonstrating the impact that including multiple cell types in 3D assays can have on therapeutic outcome in a chemotherapeutic assay.
Although filtration is commonly practiced in many laboratories, it is a critical step in preparing media and buffers, clarifying samples, removing microbial contaminants, concentrating and inline filtering gases, to name a few applications. In order to choose the correct filter for your application, you need to consider the application, the material(s) to be filtered, and other factors that will be covered in this presentation. This webinar will focus on:
An Introduction to Filtration:
• Basic principles of filtration
• Overview of membranes
• Overview of formats
Choosing the Correct Filtration Product for your Application:
• Clarification of solutions
About our Presenter:
Dr. Mark Rothenberg graduated from Emory University with his Ph.D. in Cell and Developmental Biology. Over the past 25 years, Mark has held positions in both academia and industry where he has developed an expertise in the areas of assay development and cell culture. He currently holds the position of Manager Scientific Training and Education with Corning Life Sciences.
The importance of genetic variations in drug transporters for drug disposition and response has been increasingly recognized in the past decade. The drug transporter organic anion transporting polypeptide 1B1 (OATP1B1) is genetically polymorphic and plays a major role in hepatic uptake of a variety of clinically important drugs. Predicting the pharmacokinetic effect of these genetic variants on the drug disposition is critical for understanding the inter-individual variations to drug efficacy and safety. Corning TransportoCells was introduced to support in vitro assessment of drug interaction with SLC transporter. Specially, the newly developed TransportoCells OATP1B1 SNPs, alongside with OATP1B1 wild type, offer an in vitro tool kit for studying the potential impact of genetic variants on drug PK.
This webinar will focus on the development and characterization of the newly available TransportoCells OATP1B1 genetic variants, three animal species Oatp family members and other drug transporters of emerging importance in drug development.
Primary human hepatocytes (PHHs) and other hepatic cell models possess several limitations. For instance, PHH’s large lot-to-lot variation requires qualification tests with each lot, resulting in high costs and increased lead time. Furthermore, other non-primary hepatic cells can have insufficient fold induction in some lots and conditions.
This presentation will introduce Corning® HepatoCells for ADME/Tox studies. Derived from primary human hepatocytes, Corning HepatoCells are a renewable, hepatocyte-like cell line that retains most of the physiological properties of their parental hepatocytes such as mature hepatocyte-like morphology and induction response to prototypical inducers of CYP3A4, 1A2, and 2B6. Characterization of Corning HepatoCells for ADME/Tox studies will be presented, along with data demonstrating how the model system can be used for prediction of clinical CYP induction.